# ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies

> **NCT05085548** · PHASE1 · COMPLETED · sponsor: **ProDa BioTech, LLC** · enrollment: 46 (actual)

## Conditions studied

- Advanced Pancreatic Cancer
- Solid Tumor Malignancies

## Interventions

- **DRUG:** ProAgio Dose Levels (DL) 1,2,3
- **DRUG:** ProAgio Dose Levels (DL) 4,5,6
- **DRUG:** ProAgio Dose Levels 4a,5a,6a

## Key facts

- **NCT ID:** NCT05085548
- **Lead sponsor:** ProDa BioTech, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-29
- **Primary completion:** 2025-04-24
- **Final completion:** 2026-04-10
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2026-04-27

## Collaborators

- National Cancer Institute (NCI)

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05085548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05085548, "ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05085548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*